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ABSTRACT  
Tumour infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and 
guidelines for their assessment have been published. This study aims to evaluate; (a) methods 
of TILs assessment, and (b) their prognostic significance in breast ductal carcinoma in situ 
(DCIS). Haematoxylin and Eosin sections from two clinically annotated DCIS cohorts; a 
training set (n=150 pure DCIS) and a validation set (n=666 comprising 534 pure DCIS and 132 
cases wherein DCIS and invasive breast carcinoma were coexistent) were assessed. Seven 
different scoring methods were applied to the training set to identify the most optimal 
reproducible method associated with strongest prognostic value. Among different methods, 
TILs touching ducts’ basement membrane or away from it by one lymphocyte cell thickness 
provided the strongest significant association with outcome and highest concordance rate 
[inter-cluster correlation coefficient=0.95]. Assessment of periductal TILs at increasing 
distances from DCIS (0.2mm, 0.5mm and 1mm) as well as percent of stromal TILs were 
practically challenging and showed lower concordance rates than touching TILs. TILs hotspots 
and lymphoid follicles did not show prognostic significance. Within the pure DCIS validation 
set, dense TILs were associated with younger age, symptomatic presentation, larger size, higher 
nuclear grade, comedo necrosis and oestrogen receptor negativity as well as shorter recurrence 
free interval (p=0.002). In multivariate survival analysis, dense TILs were independent 
predictor of shorter recurrence free interval (p=0.002) in patients treated with breast 
conservation. DCIS associated with invasive carcinoma showed denser TILs than pure DCIS 
(p=9.0 x10-13). Dense TILs is an independent prognostic variable in DCIS. Touching TILs 
provides a reproducible method for their assessment that can potentially be used to guide 
management.  
 
Key words: Breast ductal carcinoma in situ, infiltrating lymphocytes, assessment, recurrence.  
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INTRODUCTION 
The incidence of ductal carcinoma in situ (DCIS) of the breast has dramatically increased after 
introduction of mammographic screening programmes (1, 2). This, together with increasing 
use of breast conserving surgery for management of breast cancer, has heightened the need for 
robust and reliable predictors of disease recurrence and progression, for risk stratification of 
patients. Comparison of DCIS recurrence rates and progression (to invasive disease) with the 
rates of mastectomies, surgical re-excisions or intense course of radiotherapy suggests 
overtreatment, stemming from a lack of accurate risk stratification (3). Current application of 
molecular genetic signatures for DCIS categorisation to provide suitable individualised 
management remains challenging (4-9). 
Tumour infiltrating lymphocytes (TILs) are indicators of the adaptive immune response against 
tumours and play a cornerstone role in cancer immunotherapy (10, 11).  In previous studies on 
invasive breast cancer, dense TILs were shown to augment effect of chemotherapy providing 
better prognosis mainly in triple negative breast tumours (12, 13). Following demonstration of 
their prognostic significance in invasive breast carcinoma and their potential clinical 
application, guideline recommendations for TILs evaluation have been published (14, 15). 
However, the recommended method of TILs assessment in invasive breast carcinoma may not 
be applicable in DCIS as not all stromal TILs are directly in contact with malignant ducts and 
identification of stromal area surrounding DCIS can be confusing and ill-defined. Despite the 
reported role of TILs in DCIS (5, 16), studies utilising the invasive carcinoma guidelines for 
TILs assessment in the context of DCIS did not find any association with outcome (15, 17). 
This is likely related to the difference in nature and distribution of TILs within DCIS compared 
to invasive breast carcinoma and the sub-optimal method of their assessment. This study aims 
to identify the optimal method of TILs evaluation in DCIS in terms of reliability, 
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reproducibility and prognostic significance with recurrence through utilisation of a large well-
annotated DCIS cohort with long term follow-up.  
MATERIALS AND METHODS 
Study cohort  
This retrospective study included 982 cases diagnosed from 1990 to 2012 at Nottingham City 
Hospital, Nottingham, United Kingdom. Following histological review of tumour slides of all 
cases and retrieval of tissue blocks, representative Haematoxylin and Eosin stained sections 
from each case were prepared from 816 cases (684 pure DCIS and 132 DCIS mixed with 
invasive carcinoma). Representative sections were defined as those having the largest tumour 
burden. Clinicopathological data included patients’ age, type of presentation (whether 
symptomatic or screen-detected), DCIS tumour size, nuclear grade, presence of comedo 
necrosis, associated Paget’s disease, detailed information about management and outcome 
including surgery type, and number of operations, local radiotherapy treatment, occurrence and 
nature of local recurrence and recurrence free interval were collected from local data recording 
systems. Recurrence free interval is defined as time between first DCIS surgery and occurrence 
of ipsilateral tumour recurrence (either as DCIS or invasive carcinoma) in months. Cases with 
contralateral breast event or invasive breast carcinoma developed as a new primary tumour in 
a different quadrant were censored at the time of recurrences. For molecular characterisation 
of DCIS, oestrogen receptor immunohistochemical staining was performed in cases with 
available paraffin blocks. 4µm sections were stained on the Ventana BenchMark® ULTRA 
system (Tucson, Arizona, USA) using Ventana oestrogen receptor (SP1) Rabbit Monoclonal 
Primary Antibody as per recommended protocol.  
The cohort was split into two groups; a training set and a validation set (clinicopathological 
parameters of both sets are shown in Supplementary Table 1):  
5 
 
Training set 
The training set included 150 pure DCIS from patients older than 50 years of age with mixture 
of DCIS grades that was completely excised with free surgical margins (10mm or more) to 
avoid the confounding effect of age or margin of excision on the outcome analyses. Within a 
median follow-up period of 161 months; 41 cases (27%) developed ipsilateral recurrence.  
Validation set 
The validation set (n= 666) was further split into two subgroups; 1) Pure DCIS (n=534) which 
showed 63 ipsilateral local recurrence events (11.8%) within a median follow-up period of 109 
months; 2) DCIS with co-existent invasive breast carcinoma (n=132) to compare the pattern of 
TILs density between pure DCIS cases and cases wherein DCIS is associated with invasion. 
Supplementary Figure 1 shows the algorithm of the study cohorts.   
Scoring of TILs 
Freshly stained Haematoxylin and Eosin (4-5µm thick) full face sections were scanned using 
a high-resolution slide scanner (PANNORAMIC 250 FLASH III, 3D-HISTECH), followed by 
viewing the slides using ‘‘Pannoramic Viewer Software program, version 1.15.4’’.  In this 
study, TILs were counted manually (eyeballing) using digital images. The International 
Working Group Recommendations for TILs assessment were modified and applied to our case 
series (15). All recognisable mononuclear inflammatory cells including lymphocytes and 
plasma cells were counted (polymorphonuclear cells were excluded). TILs were assessed 
around all DCIS duct profiles up to 20 ducts (the average number of ducts within the training 
set). For cases with more than 20 malignant ducts, we divided the section field into four 
identical quadrants using the Pannoramic Viewer software, and scored TILs around five ducts 
in each quadrant in order to keep the scoring more representative especially in cases with 
heterogeneously distributed TILs. During scoring, very large (i.e., mass forming papillary 
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carcinoma, branching or confluent DCIS ducts) or very small (terminal duct-lobular units 
involved by DCIS) ducts were not considered in TILs scoring to avoid skewing of the scores 
by the effect of extremes in duct sizes. Pure encapsulated papillary carcinomas, not associated 
with adjacent DCIS, were excluded from the scoring. Any type of circumferential TILs-
infiltration was considered, including minimal, partial, subtotal and total circumferential TILs-
infiltration around ducts. TILs beyond the lesion limits, surrounding the adjacent or 
intermingled fat, normal ducts, associated lobular carcinoma in situ, regressive hyalinosis or at 
crushing artefacts were excluded from the scoring.  
In the training set, TILs were assessed using 7 different scoring methods (Table 1). These 
included: 1- Percentage of stromal TILs (assessed in a manner similar to the modified method 
for evaluation of TILs in invasive breast carcinoma. The stromal area was defined as the area 
surrounding the DCIS duct within two high-power microscopic fields and used for evaluation 
of stromal TILs percentage (15, 17, 18). In cases with numerous involved ducts, an evaluation 
of the area surrounding the whole lesion was performed, and percentage of stromal TILs in the 
total stromal area of all DCIS involved ducts was determined (5, 15, 19), 2-The mean number 
of touching TILs defined by TILs touching or within one lymphocyte cell thickness from the 
malignant ducts’ basement membrane; 3-Mean number of TILs within 0.2mm distance from 
ducts’ basement membranes; 4- Mean number of TILs located within 0.5mm distance from 
ducts’ basement membranes; 5-Mean number of TILs located within 1mm from ducts’ 
basement membranes; 6-TILs hotspots defined as the largest number of lymphoid cells 
aggregates directly surrounding or located between DCIS ducts within the boundaries of the 
lesion; and 7-Assessment of lymphoid follicles with reactive germinal centres. Counting of 
TILs at different topographic areas was carried out manually with aid of the Panoramic Viewer 
Software program scale. Overlapping TILs between adjacent ducts in each topographic area 
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were counted once. The detailed methods followed to assess TILs are summarised in Table 1 
and illustrated in Figure 1. 
To check the reliability and reproducibility of the evaluation methods, training set was scored 
using all the previous parameters by 3 observers (MST, IMM and AK). Two observers 
discussed the detailed methodology before starting their scoring, while the third observer 
scored the cases based on a written protocol without any verbal discussion. The optimal method 
for TILs assessment was determined based on the association with outcome and reproducibility 
in terms of inter-observer concordance as well as practicality, which was then applied to the 
validation set. Validation set, including the pure DCIS and mixed cohorts, was scored for 
touching TILs by 2 observers (MST and AK) to confirm reproducibility and prognostic 
significance. In mixed cases, touching TILs were scored around the DCIS component only 
while TILs adjacent to invasive tumour were not considered in the scoring. TILs scoring carried 
out by the first observer (MST) were considered in the final statistical analysis (the main 
researcher for this study). Other observers’ scores were used to check the reproducibility and 
concordance rate.  
As assessment of stromal TILs was the method used to evaluate TILs in DCIS in previous 
studies (15, 17, 18), stromal TILs was also evaluated in the pure DCIS validation set using the 
same criteria applied in training set.  
This study is ethically approved by the North West - Greater Manchester Central Research 
Ethics Committee (15/NW/0685).  
Statistical Analysis 
The optimal cut-off point for TILs density against recurrence free interval was defined using 
X-tile bioinformatics software (Yale University, version 3.6.1). TILs were classified into sparse 
infiltrates and dense infiltrates depending on these cut-off points (Supplementary Table 2). 
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For consistency, the same cut-off point used in dichotomisation touching TILs in the training 
set into sparse and dense groups was applied in the validation set. Furthermore, to mimic the 
three-tier prognostic classification system of TILs in melanoma (20) and based on the outcome 
analysis, TILs were further defined into three-groups; absent/very scanty (mean number of 
touching TILs/DCIS duct ≤5 cells), sparse (6-20 cells/DCIS duct) and dense (>20 cells/DCIS 
duct) TILs. This was based on counting TILs around DCIS ducts, in up to 20 ducts per case, 
and then the total number of TILs was divided by the number of DCIS ducts resulting in the 
mean TILs number. IBM-SPSS statistical software 22.0 (SPSS, Chicago, IL, USA) was used 
to analyse our findings. Inter-observer degree of agreement was assessed through inter-class 
correlation coefficient for continuous data and Kappa test for categorical groups. Linear 
correlation between TILs densities within different topographic areas and touching TILs was 
analysed using Spearman’s test. Kaplan–Meier curves and log-rank test were used for 
univariate survival analyses while Cox regression model was used for the multivariate analysis 
for patients treated with breast conserving surgery. Two tailed p-value <0.05 was considered 
as statistically significant. 
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RESULTS 
This study included two sets of cases; a training set comprising 150 pure DCIS cases scored 
by three observers using 7 different scoring methods and a validation set (n=666 cases 
comprising 534 pure DCIS and 132 DCIS cases with co-existing invasive carcinoma) which 
was scored for touching and stromal TILs by 2 observers. 
Training set  
The concordance rate of TILs assessment using different methods between the three observers 
is summarised in Supplementary Table 3. The highest degree of inter-observer agreement 
was observed in touching TILs (Inter-cluster correlation coefficient=0.96) whereas the least 
concordance rate was found with the percentage of stromal TILs evaluation (Inter-cluster 
correlation coefficient=0.79) which is the recommended method in invasive breast carcinoma.    
Mean TILs counts within different topographic areas around DCIS are summarised in 
Supplementary Table 4. The mean count of TILs increased from 37 cells/DCIS duct at 
touching area to 482 cells/DCIS duct within 1mm distance. Largest hotspot density ranged 
from 20 to 6,000 cells while percentage of stromal TILs ranged from 1-65%. Mean TILs 
density increased by 4-fold between touching and within 0.2mm distance, while it increased 
only by 2-fold and 1.5-fold from 0.2mm to 0.5mm and from 0.5mm to 1mm distances, 
respectively. No cases with absent TILs were observed. Touching TILs showed positive linear 
correlation with TILs within the other topographic areas (Supplementary Table 5). The 
highest correlation was observed between touching TILs and TILs counted at 0.2mm distance 
(Spearman’s correlation =0.854, p=1x10-13). Counting TILs in farer areas away from the ducts 
showed less correlation with touching TILs.  
Percentage of the cases with dense TILs were 53%, 57%, 59% and 65% for touching TILs and 
within 0.2mm, 0.5mm and 1mm from DCIS ducts, respectively. Dense hotspots were observed 
in 31% of cases while dense stromal TILs were observed in 49% of cases. Lymphoid follicles 
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were observed in 31 cases only (21%). The percentages of cases with dense and sparse TILs in 
context of each topographic area as well as the percentage of cases that developed local 
recurrence within each category and their association with recurrence free interval are 
summarised in Table 2. Examples of dense and sparse TILs are shown in Figure 2. 
More than 60% of DCIS cases that developed local recurrence showed dense TILs irrespective 
of the topographic area used for assessment (Touching, 0.2mm distance, 0.5mm, 1mm and % 
stromal TILs). Only five cases (12%) from those developed local recurrence showed lymphoid 
follicle formations. Dense TILs infiltrate at different compartments showed statistically 
significant association with shorter recurrence free interval (p=4.7x10-6, p=0.001, p=0.002 and 
p=0.001 for touching TILs and TILs within 0.2mm, 0.5mm and 1mm distances, respectively). 
Stromal TILs density was also associated with shorter recurrence free interval but with less 
statistical significance (p=0.02) than dense TILs defined in context of circumferential distances 
from the malignant ducts. Neither hotspots nor lymphoid follicles formation showed significant 
association with recurrence (p=0.09 and p=0.15, respectively). Results of univariate survival 
analysis are detailed in Table 2. Supplementary Figure 2 shows Kaplan Meier survival curves 
for TILs density in different compartments and recurrence free interval.  
Validation set 
The concordance rate between the two observers evaluated touching TILs in the validation set 
was comparable to the training set (Inter-cluster correlation coefficient=0.95). Dichotomisation 
of touching TILs using 20 cells/DCIS duct as a cut-off point, showed that 239 cases (45%) had 
dense TILs infiltrate while 55% of cases showed sparse infiltrate.   
Association of TILs density with other clinicopathological parameters  
Dense touching TILs were associated with parameters characteristic of aggressive tumour 
behaviour including younger age, symptomatic presentation and larger tumour size. Only 8 
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cases (14%) of low nuclear grade lesions showed dense TILs in comparison with 33% and 54% 
of intermediate and high nuclear grade lesions, respectively (p=1.1x10-9). Half of the cases 
(50%) associated with comedo necrosis harboured dense TILs while this was observed only in 
32% of cases without comedo necrosis (p=0.00009). Approximately two thirds (69%) of DCIS 
cases associated with Paget’s disease showed dense TILs infiltrate compared with 46% of 
patients without Paget’s disease (p=0.025). 72% of oestrogen receptor negative DCIS showed 
dense TILs infiltrate while only 36% of oestrogen receptor positive cases showed high TILs 
density (p=1.04x10-10). 
Moreover, dense TILs were observed in 80% of DCIS mixed with invasion compared with 
54% of pure grade-matched DCIS (χ2=51.29, p=8.96x10-13). This association was observed 
also when touching TILs was assessed as a continuous variable (p=3.14x10-12) 
(Supplementary Figure 3). The association between TILs density and various 
clinicopathological parameters are summarised in Table 3. 
Outcome analysis  
Ipsilateral local recurrence rate in the pure DCIS validation cohort was 11.8% (n=63). 
Recurrence occurred in 39/239 cases with dense TILs (62% from total recurrences), in 
comparison with 24/295 cases with sparse TILs (38% from total recurrences). Within patients 
treated with breast conserving surgery, local recurrence was reported in 24/80 cases with dense 
TILs (56%) compared to 19/139 cases with sparse infiltrate (44%). When assessed based on 
oestrogen receptor status, there were 22 recurrent events among oestrogen receptor positive 
DCIS with dense TILs (n=114) compared with 40 events among cases with sparse TILs 
(n=198). Among oestrogen receptor negative DCIS cases, 14/83 cases with dense TILs had 
local recurrence while only 1/33 cases with sparse TILs experienced a recurrence.  
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When TILs were classified into three categories defined as; absent/very scanty TILs (mean 
number of touching TILs/DCIS duct ≤5 cells), sparse TILs (from 6-20 cells/DCIS duct) and 
dense TILs (>20 cells/DCIS duct), recurrence occurred in 1/37 patients (3% of the group, 1.5% 
of the total recurrences), 23/258 patients (9% of the group, 36.5% of the total recurrences) and 
39/239 (16% of the group, 62% of the total recurrences); respectively.   
In univariate survival analysis using two-tier classification system of TILs, dense TILs showed 
statistically significant association with shorter recurrence free interval. This was observed 
when the analysis was conducted on the whole cohort (p=0.002), or confined to patients treated 
with breast conserving surgery (p=0.001). In context of oestrogen receptor status, dense TILs 
infiltrate was associated with shorter recurrence free interval in both oestrogen receptor 
positive (p=0.011) and oestrogen receptor negative (p=0.025) DCIS. Supporting the 
reproducibility of touching TILs evaluation in outcome prediction, univariate analysis using 
the second observer’s scoring showed significant association with recurrence in the whole 
cohort and in patients treated with breast conserving surgery (p=0.0001 and p=0.004, 
respectively). Moreover, when the analysis was conducted using the average score between the 
two observers, it also showed significant association (p=0.002, p=0.01 for the whole cohort 
and for patients treated with breast conserving surgery, respectively).  
Similar findings were observed when the three-tier classification system was used in the 
univariate analysis where dense TILs infiltrate was associated with shorter recurrence free 
interval in the whole cohort and breast conserving surgery treated patients (p=0.005 and 
p=0.004; respectively). The detailed results of univariate analyses between different 
clinicopathological parameters as well as TILs against recurrence free interval, and Kaplan-
Meier curves are provided in Table 4 and Figure 3, respectively. Interestingly, there was no 
statistically significant association between recurrence free interval and TILs density when 
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assessed based on the percentage of overall stromal TILs (p=0.117 for the whole cohort and 
p=0.138 for patients treated with breast conserving surgery).  
Cox regression multivariate model with other clinicopathological parameters including 
patient’s age, tumour size, nuclear grade, presence of comedo necrosis, adjuvant radiotherapy 
and oestrogen receptor status showed that dense touching TILs is the only independent 
predictor of shorter recurrence free interval in patients treated with breast conserving surgery 
(Hazard ratio =2.6, 95% Confident interval = 1.41-4.7, p=0.002) (Table 5). 
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DISCUSSION 
Currently, clinicopathological parameters used for DCIS risk stratification such as age, nuclear 
grade, tumour size and associated comedo necrosis are still insufficient to accurately estimate 
recurrence risk associated with DCIS (21, 22). TILs in DCIS are thought to have a role in 
tumour behaviour and progression; however, there are currently no consensus guidelines to 
evaluate TILs in clinical practice. Previous studies of TILs evaluation in DCIS neither used 
clear or uniform definition of the stromal area surrounding DCIS for TILs assessment nor 
identified cut-off points that can prognostically stratify DCIS. Some studies used the 
International Working TILs Group guidelines (14) with modification to DCIS and assessed 
percentage of stromal TILs at the stroma within the boundaries of the whole lesion (5, 19). 
Pruneri et.al (15) defined stromal TILs surrounding DCIS as those located at the area within 
two high power microscopic fields form the DCIS ducts and this method was adopted by other 
authors (17, 18, 23). These studies have reported lack of association between TILs density and 
DCIS recurrence. In the current study, TILs were assessed in a large cohort of DCIS with long-
term follow-up data using various scoring methods to determine the most reproducible method 
that can additionally provide prognostic value. Prognostic stratification system has also been 
proposed to facilitate TILs application in DCIS in routine practice. 
Assessment of TILs in the training set revealed that touching TILs is the optimal method for 
TILs scoring in DCIS. This conclusion was based on several criteria. Firstly, touching TILs 
had the highest concordance rate between the observers with or without prior methodology 
discussion. Secondly, they were positively correlated with TILs in the other topographic areas, 
hence representing TILs density within the whole lesion without requirement to assess TILs in 
wider areas around ducts which is time consuming. Thirdly, touching TILs assessment was the 
easiest and fastest method which can be performed without the need for accurate measurement 
of distance around ducts or adjustment of the scale and area’s dimensions. Moreover, 
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assessment of touching TILs avoids confusion/variability in scoring cells within overlapping 
areas between adjacent ducts. Lastly, touching TILs showed the strongest significant 
association with other prognostic clinicopathological parameters and DCIS outcome 
(recurrence free interval).  
In this study, touching TILs showed significant association with recurrence free interval in both 
training and validation cohorts as well as when the analysis was conducted using different 
observers’ scores. Notably, dense touching TILs were associated with shorter recurrence free 
interval when the analysis was performed either in the whole cohort or when confined only to 
patients treated with breast conserving surgery. Importantly, touching TILs was an independent 
prognostic factor for DCIS recurrence in patients treated with breast conserving surgery 
regardless of other known determinants of tumour behaviour (24-27). 
Interestingly, the percentage of overall stromal TILs assessed using the same methods for TILs 
evaluation described in the previous studies (5, 15, 17-19) showed not only the least 
concordance rates but also variability in association with the outcome. Unlike stromal TILs 
evaluation in invasive breast carcinoma, the low inter-observer and intra-observers’ agreement 
may reflect the subjectivity of assessment of stromal TILs in DCIS, even with the use of 
predefined criteria of stromal area surrounding DCIS. 
Studies of TILs in invasive breast carcinoma reported associations between TILs and better 
prognosis especially in triple negative breast cancer and supported their synergistic effect with 
chemotherapy (12, 13). By contrast, the current study demonstrates that dense TILs in DCIS 
are associated not only with other potential risk factors for aggressive DCIS behaviour but also 
with increased risk of tumour recurrence and progression. Supporting our results, Pruneri et 
al. reported that dense TILs are correlated with more aggressive DCIS (15). Hendry et al. have 
also reported dense TILs are associated with high grade, comedo type, oestrogen receptor 
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negative and Her2 positive DCIS lesions (17). Although both studies failed to find a significant 
association between TILs density and tumour outcome, this might be due to different 
assessment methodology. A recent molecular study showed that dense TILs were associated 
with aggressive DCIS. Copy number variation in DCIS with dense TILs was shown to be more 
profound than lesions with low TILs density which might indicate the higher immunoediting 
capability of DCIS with dense TILs making them more likely to progress and recur (17).  In 
addition, dense TILs were associated with high DCIS Oncotype DX score (28), providing 
evidence to support our results that dense TILs are associated with poor outcomes in DCIS. 
Association between dense TILs infiltrate and poor prognosis has also been reported in oral, 
colonic, prostatic and pancreatic preinvasive neoplasia (29, 30). 
Interestingly, dense TILs were associated with shorter recurrence free interval irrespective of 
oestrogen receptor expression in DCIS. This might indicate that the crosstalk between the 
immune microenvironment and tumour cells contributing to DCIS recurrence and/or 
progression is unrelated to oestrogen receptor pathway. Comparing TILs density in DCIS 
associated with invasion with pure DCIS indicates more TILs density in the former. This 
finding supports the hypothesised role of inflammatory cells in DCIS progression and 
aggressiveness (5, 16, 31, 32). TILs density assessment and reporting in the routine practice 
for DCIS diagnosed by core biopsy may provide a predictive factor for presence of invasion in 
these lesions as previously observed (33, 34). 
Involvement of different immune cell subpopulations in DCIS behaviour has been speculated. 
Regulatory T cells (T-regs) play key roles in tumour evasion from the immune system (35). 
Homeostasis of the immune response in the body is regulated by T-regs, however a paradoxical 
action may occur through over-suppression of the immune cells attacking the tumour cells 
leading to tumour progression (36).  It was shown that high grade DCIS lesions harbour higher 
percentage of FOXP3+ cells (19). Moreover, tumour cells surrounded by dense TILs may 
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produce some protective proteins to evade the host immune system. Thompson et al. have 
reported that DCIS with dense TILs show higher level of programmed cell death ligand 1 
(PDL-1) positive tumour cells (5). This was supported with two similar studies that 
characterised immune microenvironment in DCIS (17, 19). Although the role of B-
lymphocytes in tumour immunity and behaviour is unclear, a study on a small cohort of DCIS 
by Miligy et al., showed increased B lymphocytes infiltrate was associated with increased 
recurrence liability and with other poor outcome parameters (37).  
In conclusion, using touching TILs as an assessment method for TILs in Haematoxylin and 
Eosin stained full-face DCIS sections is a reproducible and practical method to predict tumour 
behaviour and progression. Application of this method in routine practice would aid in risk-
stratification of DCIS for improved, individualised management.  
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Figures and Figures’ legends: 
 
Figure 1: Parameters of TILs assessment; A) Touching lymphocytes (x40) defined by lymphocytes that 
touch the basement membrane (BM) or are located within one lymphocyte cell thickness distance from 
basement membrane (yellow arrows); inset closer view for touching TILs, B) TILs assessment within 
0.2mm, 0.5mm and 1.0mm distance from the involved ducts, and C) evaluation of hotspots (largest number 
of lymphoid cells aggregates within the lesion as shown in area surrounded by black dashed circle).  
 
 
Figure 2: Touching TILs density around DCIS; A) Dense infiltrate where mean number of touching TILs 
is more than 20 cells/DCIS duct, B) High power view for dense touching TILs, and C) Sparse infiltrate 
where the mean number of touching TILs within the lesion is 20 cells or less/DCIS duct.  
 
 
Figure 3: Kaplan-Meier Curves showing association of touching TILs density (Two-groups) with 
Recurrence free interval (in months); A) all cases irrespective of surgical treatment, B) cases treated with 
breast conserving surgery, (C and D) according to oestrogen Receptor status, as well as when TILs density 
defined as three-groups in; E) the whole cohort, and F) breast conserving surgery treated patients. 
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Table 1. Methods and parameters of Tumour Infiltrating Lymphocytes (TILs) assessment 
in DCIS  
Methods for evaluation of TILs in DCIS 
1- TILs were assessed in Haematoxylin and Eosin-stained sections. Only full-face sections from surgically 
excised specimen were assessed. Lesions diagnosed on core biopsy were not included.  
2- One representative section (4µm), per patient, which has the largest tumour burden, was selected for 
TILs assessment.     
3- All mononuclear inflammatory cells apart from polymorphonuclear leukocytes were counted.  
4- TILs within the boundaries of the DCIS were assessed. TILs beyond the tumour limits, surrounding 
normal ducts/lobules, adjacent fatty tissue, lobular carcinoma in situ, regressive hyalinosis, crushed 
artefacts or sites of previous biopsy were excluded.  
5- TILs within tumour cells (intra-tumour TILs) were not assessed.  
6- TILs were assessed around all malignant ducts up to 20 ducts. For lesions with more than 20 malignant 
ducts, we assessed TILs surrounding 20 ducts (5 ducts from each quadrant of the lesion).  
7- TILs were assessed around average sized ducts only (case specific). TILs around very large DCIS ducts 
such as mass forming papillary carcinoma, branching or confluent DCIS ducts or very small ducts such 
as terminal duct-lobular system involved by DCIS were excluded.  
8- Any TILs infiltrating the ducts’ circumference were considered. Overlapping TILs between adjacent 
ducts were counted once.  
Parameters used for TILs assessment* 
A- Estimation of stromal TILs (as previously published): 
 The stromal area was defined as the area surrounding the DCIS duct within two high power microscopic 
fields and used for evaluation of stromal TILs percentage (15, 17, 18). In cases with numerous involved 
ducts, an evaluation of the area surrounding the whole lesion was performed, and percentage of stromal 
TILs in the total stromal area of all DCIS involved ducts was determined (5, 15, 19). 
B-Estimation of periductal TILs (based on counting TILs around all DCIS duct profiles up to 20 ducts)   
1- Evaluation of the mean number of TILs touching DCIS involved ducts (defined as TILs touching or 
within one lymphocyte cell thickness from ducts’ basement membrane).  
2- Evaluation of the mean number of TILs within 0.2mm distance from the ducts   
3- Evaluation of mean number of TILs within 0.5mm distance from the ducts 
4- Evaluation of mean number of TILs with 1.0mm distance from the ducts 
5- Evaluation of the TILs hotspot defined by largest number of lymphoid aggregates directly surrounding 
or located between DCIS ducts within the boundaries of the lesion 
6- Evaluation of lymphoid follicles formations with reactive germinal centres in the stroma directly 
surrounding or located between DCIS ducts within the boundaries of the lesion.   
*All parameters were assessed in the training set while touching and stromal TILs assessment were 
conducted to validation set. 
 
  
24 
 
Table 2: Frequency of TILs density in different topographic areas and their association with 
outcome in terms of recurrence free interval in the training set  
Parameter TILs density (mean 
number of TILs/DCIS 
duct as cut-off) 
Number of 
cases (%) 
Recurrence 
(%) 
p-value (Log 
rank test) 
Touching TILs (Two-tier 
system)  
Sparse (≤ 20) 
Dense (>20) 
70 (47) 
80 (53) 
6 (15) 
35 (85) 
4.7x10-6 
Touching TILs (Three-tier 
system) 
Absent/very scanty (≤5) 
Sparse (6-20) 
Dense (>20) 
7 (5) 
63 (42) 
80 (53) 
0 (0) 
6 (15) 
35 (85) 
2.0x10-5 
TILs at 0.2mm distance  Sparse (≤ 60) 
Dense (> 60) 
64 (43) 
86 (57) 
8 (20) 
33 (80) 
0.001 
TILs at 0.5mm distance  Sparse (≤ 100) 
Dense (> 100) 
61 (41) 
89 (59) 
8 (20) 
33 (80)  
0.002 
TILs at 1.0mm distance  Sparse (≤ 120) 
Dense (> 120) 
53 (35) 
97 (65) 
6 (15) 
35 (85) 
0.001 
Hotspot Sparse (≤ 1200) 
Dense (>1200) 
103 (69) 
47 (31) 
33 (80)  
8 (20) 
0.089 
Lymphoid follicles No 
Yes 
119 (79) 
31 (21) 
36 (88) 
5 (12) 
0.150 
Percentage of Stromal TILs   Sparse (≤ 5% ) 
Dense (>5%) 
77 (51) 
73 (49) 
15 (37) 
26 (63) 
0.020 
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Table 3: Correlation between TILs density (based on mean number of touching TILs with cut-off 
20 cells/DCIS duct) and clinicopathological parameters in the validation set 
Parameter 
TILs density 
Chi square 
(χ2) 
p value Dense 
N (%) 
Sparse 
N (%) 
Patient age 
   ≤50 years 
   >50 years 
 
71 (52) 
168 (42) 
 
65 (48) 
230 (58) 
4.09 0.043 
Presentation  
   Screening 
   Symptomatic 
 
114 (41) 
125 (49) 
 
166 (59) 
129 (51) 
3.89 0.049 
DCIS Size 
   ≤20mm 
   >20mm 
 
85 (37) 
152 (51) 
 
147 (63) 
147 (49) 
10.66 0.001 
DCIS Grade 
   Low 
   Moderate 
   High 
 
8 (14) 
44 (33) 
187 (54) 
 
49 (86) 
88 (67) 
158 (46) 
41.18 1.1x10-9 
Comedo type necrosis  
   Yes 
   NO 
 
185 (50) 
54 (32) 
 
182 (50) 
113 (68) 
15.16 0.00009 
Associated Paget’s disease 
   Yes            
   No 
 
18 (69) 
156 (46) 
 
8 (31) 
180 (54) 
5.03 0.025 
Oestrogen receptor status  
   Negative 
   Positive 
 
83 (72) 
114 (36) 
 
33 (28) 
198 (64) 
41.73 1.04x10-10 
Type of DCIS 
   Mixed with invasion 
   Pure DCIS 
 
105 (80) 
239 (45) 
 
27 (20) 
295 (55) 
51.29 8.96x10-13 
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Table 4: Univariate association of TILs and other clinicopathological parameters with recurrence 
free interval  
Parameter Recurrence (%) p-value 
Patient age 
   ≤50 years 
   >50 years  
 
21 (33) 
42 (67) 
0.042 
Presentation  
   Symptomatic 
   Screening 
 
36 (57) 
27 (43) 
0.110 
DCIS Size 
   ≤20mm 
   >20mm 
 
40 (65) 
22 (35) 
0.002 
DCIS Grade  
   Low 
   Intermediate 
   High 
 
3 (5) 
15 (24) 
45 (71) 
0.409 
Comedo type necrosis  
   No 
   Yes 
 
25 (40) 
38 (60) 
0.191 
Associated Paget’s disease  
   No  
   Yes 
 
32 (89) 
4 (11) 
0.552 
Final Operation type 
   Mastectomy 
   Breast conserving surgery  
 
20 (32) 
43 (68) 
1.1x10-6 
Radiotherapy  
   No 
   Yes 
 
55 (87) 
8 (13) 
0.714 
Oestrogen receptor status  
   Negative 
   Positive 
 
15 (27) 
40 (73) 
0.992 
TILs density (Touching TILs) Two-tier system*  
   Sparse 
   Dense 
 
24 (38) 
39 (62) 
0.002 
TILs density (Touching TILs) Three-tier 
system*  
   Absent/Very scanty  
   Sparse  
   Dense  
 
1 (1.5) 
23 (36.5) 
39 (62) 
0.005 
TILs density (stromal TILs) 
   Sparse 
   Dense 
 
47 (75) 
16 (25) 
0.117 
*Classifications (Definitions) of various touching TILs densities 
- Two-tier (Two-groups) classified as Sparse where the mean number of TILs within the lesion is 20 
cells/DCIS duct or less and Dense where the mean number of TILs within the lesion is more than 20 
cells/DCIS duct. 
- Three-tier (Three-groups) classified as Absent/very scanty where the mean number of TILs within 
the lesion in 0-5 cells/DCIS duct, Sparse where the mean number of TILs within the lesion is 6-20 
cells/DCIS duct and Dense where the mean number of TILs within the lesion is more than 20 
cells/DCIS duct. 
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Table 5: Multivariate analysis results (Cox regression model) * 
Parameters 
Hazard ratio 
(HR) 
95.0% confident interval (CI) Significance 
p-value  Lower Upper 
Patient Age 0.599 0.318 1.127 0.112 
DCIS Size 0.755 0.403 1.415 0.381 
DCIS Grade 1.531 0.899 2.608 0.117 
Comedo Type necrosis 0.639 0.341 1.197 0.162 
Radiotherapy 0.423 0.172 1.037 0.060 
Oestrogen receptor status 0.934 0.477 1.829 0.841 
Dense TILs 2.573 1.412 4.690 0.002 
     *Performed for patients treated with Breast conservative surgery only.  
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Figure 1 
 
Figure 1: Parameters of TILs assessment; A) Touching lymphocytes (x40) defined by lymphocytes that 
touch the basement membrane (BM) or are located within one lymphocyte cell thickness distance from 
basement membrane (yellow arrows); inset closer view for touching TILs, B) TILs assessment within 
0.2mm, 0.5mm and 1.0mm distance from the involved ducts, and C) evaluation of hotspots (largest number 
of lymphoid cells aggregates within the lesion as shown in area surrounded by black dashed circle).  
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Figure 2 
 
Figure 2: Touching TILs density around DCIS; A) Dense infiltrate where mean number of touching TILs 
is more than 20 cells/DCIS duct, B) High power view for dense touching TILs, and C) Sparse infiltrate 
where the mean number of touching TILs within the lesion is 20 cells or less/DCIS duct.  
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Figure 3 
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Figure 3: Kaplan-Meier Curves showing association of touching TILs density (Two-groups) with 
recurrence free interval (in months); A) all cases irrespective of surgical treatment, B) cases treated with 
breast conserving surgery, (C and D) according to oestrogen Receptor status, as well as when TILs density 
defined as three-groups in; E) the whole cohort, and F) breast conserving surgery treated patients. 
 
 
 
Supplementary Figures  
 
 
Supplementary Figure 1: Algorithm for Study Cohort   
 
 
 
 
 
 
  
 
Supplementary Figure 2: Kaplan-Meier curves showing association between TILs density within different 
topographic areas and recurrence free interval (RFI) (in months) for training set; a) Touching TILs (two-
tier), b) Touching TILs (three-tier), c) TILs within 0.2mm distance, d) TILs within 0.5mm distance, e) TILs 
within 1mm distance, and f) Stromal TILs 
 
 
Supplementary Figure 3: Box and Plot shows difference in TILs density between pure DCIS and DCIS 
associated with invasive breast cancer (IBC) (p-value conducted from Mann-Whitney test).  
 
 
 
 
 
 
 
Supplementary Tables   
Supplementary Table 1: Clinicopathological characteristics of the cases in the training and 
validation sets  
Parameter 
Training set (n=150) 
Number of cases (%) 
Validation set (n=534) 
Number of cases (%) 
Patient Age 
   ≤ 50 years 
   > 50 years  
  
0 (0) 
150 (100) 
 
136 (25) 
398 (75) 
Presentation  
   Symptomatic 
   Screening 
 
78 (52) 
72 (48) 
 
254 (48) 
280 (52) 
DCIS Size 
   ≤ 20mm  
   >20mm 
 
78 (52) 
67 (45) 
 
232 (43) 
299 (56) 
DCIS Grade  
   Low 
   Intermediate 
   High 
 
11 (8) 
20 (13) 
119 (79) 
 
57 (11) 
132 (25) 
345 (64) 
Comedo type necrosis  
   No 
   Yes 
 
45 (30) 
105 (70) 
 
167 (31) 
367 (69) 
Associated Paget’s disease  
   No  
   Yes 
   N/A 
 
106 (71) 
6 (4) 
38 (25) 
 
336 (63) 
26 (5) 
172 (32) 
Estrogen receptor status  
   Positive  
   Negative 
 
80 (64) 
45 (36) 
 
312 (73) 
116 (27) 
Final operation type*  
   Mastectomy 
   Breast conserving surgery  
 
86 (57) 
64 (43) 
 
314 (59) 
219 (41) 
Radiotherapy**  
   No 
   Yes 
 
127 (85) 
23 (15) 
 
139 (64) 
80 (36) 
Recurrence  
   No 
   Yes 
 
109 (73) 
41 (27) 
 
471 (88) 
63 (12) 
          N/A: Data not available 
         *One case in the validation set had no surgical data. 
         **For patients treated with breast conserving surgery.   
 
  
Supplementary Table 2: Cut-off points of mean TILs count/DCIS duct as generated by the X-tile 
software based on association with patient’s outcome (recurrence free interval).   
Parameter 
Definitions of TILs density   
Sparse Dense  
Mean count of 
Touching TILs * 
≤20 cells  >20 cells 
Mean count of TILs 
within 0.2mm distance * 
≤60 cells  >60 cells 
Mean count of TILs 
within 0.5mm distance * 
≤100 cells  >100 cells 
Mean count of TILs 
within 1mm distance * 
≤120 cells  >120 cells 
Hotspots Largest hotspot within the lesion’s 
boundaries compromising 1200 
cells or less 
Largest hotspot within the lesion’s 
boundaries compromising more 
than 1200 cells 
Stromal TILs TILs represent 5% or less from the 
total surrounding stromal area 
TILs represent more than 5% of 
total surrounding stromal area  
*Represent mean number of TILs count within a specified area/DCIS duct. 
 
Supplementary Table 3: TILs Inter-rater concordance results in the training set 
Parameter Intra-cluster correlation coefficient 
between all observers 
Mean TILs count Touching ducts 0.96 
Mean TILs count within 0.2mm distance   0.89 
Mean TILs count within 0.5mm distance   0.92 
Mean TILs count within 1mm distance   0.90 
Hotspots 0.89 
Lymphoid follicles* 0.86 
Stromal TILs percentage  0.79 
*Performed using Kappa test between first and second observers.  
 
Supplementary Table 4: Results of TILs assessment in the training set 
 Mean count 
of Touching 
TILs/DCIS 
duct  
Mean count of 
TILs at 0.2mm 
distance/DCIS 
duct 
Mean count of 
TILs at 0.5mm 
distance/DCIS 
duct 
Mean count of 
TILs at 1.0mm 
distance/DCIS 
duct 
Hotspot* Percentage of 
stromal TILs 
(%) 
 Mean 37 144 319 482 1010 13 
 Median 20 80 135 250 500 5 
 Minimum 4 10 20 50 20 1 
 Maximum 120 800 2000 3000 6000 65 
**Defined as largest number of lymphoid cell aggregates within the boundaries of the DCIS.  
  
Supplementary Table 5: Correlation between Touching TILs scores and TILs scores at other 
topographic areas (training set) 
Parameter Spearman’s 
correlation  
p value  
Mean TILs count within 0.2mm distance   0.85 1.0x10-13 
Mean TILs count within 0.5mm distance   0.75 1.0x10-13 
Mean TILs count within 1mm distance   0.69 1.0x10-13 
Hotspot 0.57 1.1x10-13 
Percentage of stromal TILs 0.69 1.0x10-13 
 
 
